Preparation method and application of suvorexan intermediate

The treatment of R-based protected 1,2-ethylenediamine under mild conditions by Grubbs catalyst solves the problems of high cost and harsh conditions for the preparation of Suvoretan intermediates, and realizes the preparation of green and environmentally friendly intermediates, which is suitable for industrial production.

CN112574181BActive Publication Date: 2024-11-22TIANJIN PHARMA GROUP CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201910940171.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2019-09-30
Publication Date
2024-11-22
Estimated Expiration
2039-09-30

AI Technical Summary

Technical Problem

The existing preparation methods for Suvoretan intermediates use high-cost chiral raw materials, highly toxic compounds, strong acids and strong bases, and the reaction conditions are harsh, making it difficult to achieve industrial production.

Method used

The reaction was carried out under mild conditions, and the R-based 1,2-ethylenediamine was used as the starting material to avoid the use of chiral raw materials and highly toxic compounds. The gentle solvent and suitable acid binding agent were used to achieve Suvorai. Green and environmentally friendly preparation of bio-intermediates.

Benefits of technology

It reduces the cost of raw materials, avoids the use of high temperatures and strong acids and alkalis, improves the safety of reaction and product purity, and is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002222621830000021
    Figure BDA0002222621830000021
  • Figure BDA0002222621830000041
    Figure BDA0002222621830000041
  • Figure BDA0002222621830000042
    Figure BDA0002222621830000042
Patent Text Reader

Abstract

The present invention provides a preparation method and application of a suvorexan intermediate, and relates to the technical field of chemical synthesis. The preparation method of the suvorexan intermediate comprises the following steps: (e) reacting a compound of formula IV under the action of a Grubbs catalyst to obtain a compound of formula V. The present invention innovatively uses a Grubbs catalyst (Grubbs second-generation catalyst) to construct a seven-membered nitrogen-containing chiral heterocycle of a suvorexan intermediate, and does not require the use of methyl vinyl ketone, a flammable and highly toxic compound, or flammable and explosive toxic gases, or the reaction under strong acid, strong base and high temperature conditions, thereby avoiding the generation of a large amount of acid solution, alkali solution and high temperature operation, and has mild reaction conditions, is green and environmentally friendly, has a high safety factor, and is easy to industrialize.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of chemical synthesis, and in particular to a preparation method and application of a suvorexan intermediate. Background Art

[0002] Insomnia is the most common sleep disorder, with about 30-50% of adults experiencing symptoms of insomnia, and 10-15% of them diagnosed with insomnia. Although insomnia is associated with many serious physical and mental illnesses, people have paid far less attention to it. For a long time, insomnia was only defined as a symptom of other diseases, so there was little progress in its understanding and treatment.

[0003] At present, the drugs used in clinical treatment of insomnia mainly include benzodiazepine receptor agonists, melatonin receptor agonists and antidepressants with hypnotic effects, but most of them are not used to treat insomnia, but to have a sedative effect. Orexin is a neuropeptide produced by hypothalamic neurons, which plays an important role in regulating the sleep-wake system and maintaining wakefulness. Suvorexant can selectively antagonize this receptor to promote sleep. It is clinically used to treat insomnia characterized by difficulty falling asleep or difficulty in maintaining sleep.

[0004] Suvorexant, chemically known as 5-chloro-2-[(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]-1,3-benzoxazole (CAS registration number 1030377-33-3), was developed by Merck and approved by the U.S. FDA in August 2014. It is the first approved orexin receptor inhibitor and is marketed under the trade name Belsomra.

[0005] Suvorexant has one chiral center, located at the 5th position of the seven-membered nitrogen-containing heterocycle, and the absolute configuration is R-type. The synthesis of Suvorexant mainly revolves around this seven-membered nitrogen-containing chiral heterocycle. At present, some documents, such as: US2008 / 132490, Org.Process Res.Dev.2011,15:367-375, WO2012148553, J.Am.Chem.Soc.2011,133:8362-8371, Org.Lett.,2012,14(13):3458-3461, Angew.Chem.Int.Ed.2011,50,11511-11515, J.Med.Chem.,2010,14(53):5320-5332, Chin.Chem .Lett, 2015, 1(26): 103-107, Tetrahedron Lett, 2014, 42(55): 5778-5780, etc. In order to obtain the intermediate seven-membered nitrogen-containing chiral heterocycle during the preparation process, some reactions use chiral raw materials for preparation, which is costly; some reactions use the highly toxic compound methyl vinyl ketone for construction; some reactions use a large amount of strong bases and strong acids, which produces too much waste acid and waste base; some reactions have too high temperatures, harsh reaction conditions, high risk factors, and are difficult to achieve industrialization.

[0006] In view of this, the present invention is proposed. Summary of the invention

[0007] The main purpose of the present invention is to provide a preparation method and application of a suvorexant intermediate, in order to at least partially solve at least one of the above technical problems.

[0008] As a first aspect of the present invention, the present invention provides a method for preparing a suvorexan intermediate, comprising the following steps: (e) reacting a compound of formula IV under the action of a Grubbs catalyst to obtain a compound of formula V, wherein the reaction formula is as follows:

[0009]

[0010] Wherein, R shown in the structural formula of the compound of formula IV and the compound of formula V is selected from Cbz, Boc, Fmoc, Teoc, Pht, Tos, Tfa, Trt, Dmb, PMB or Bn.

[0011] It should be noted that Cbz represents benzyloxycarbonyl, Boc represents tert-butyloxycarbonyl, Fmoc represents t-butyloxycarbonyl, Teoc represents trimethylsilylethoxycarbonyl, Pht represents phthaloyl, Tos represents p-toluenesulfonyl, Tfa represents trifluoroacetyl, Trt represents trityl, Dmb represents 2,4-dimethoxybenzyl, PMB represents p-methoxybenzyl, and Bn represents benzyl. The above groups can selectively protect the amino group and can be deprotected under certain conditions.

[0012] The present invention innovatively uses the Grubbs catalyst (Grubbs second-generation catalyst) for the construction of a seven-membered nitrogen-containing chiral heterocycle as a suvorexan intermediate; the reaction conditions are mild, there is no need to use the flammable and highly toxic compound methyl vinyl ketone, there is no need to use flammable and explosive toxic gases, there is no need to react under strong acid, strong alkali and high temperature conditions, the generation of a large amount of acid solution, alkali solution and high-temperature operation can be avoided, the invention is green and environmentally friendly, has a high safety factor and is easy to industrialize.

[0013] Furthermore, in the step (e), the reaction temperature is 70-90°C.

[0014] Among them, typical but non-limiting reaction temperatures can be, for example, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C or 90°C.

[0015] Furthermore, in the step (e), the molar ratio of the compound of formula IV to the Grubbs catalyst is (2-3):1.

[0016] Wherein, typical but non-limiting molar ratios of the compound of formula IV and Grubbs catalyst are 2:1, 2.1:1, 2.2:1, 2.3:1, 2.4:1, 2.5:1, 2.6:1, 2.7:1, 2.8:1, 2.9:1 or 3:1.

[0017] Furthermore, the preparation method of the compound of formula IV comprises the following steps: (d) reacting the compound of formula III with 4-halobutene to obtain the compound of formula IV, and the reaction formula is as follows:

[0018]

[0019] Wherein, R shown in the structural formula of the compound of formula III and the compound of formula IV is selected from Cbz, Boc, Fmoc, Teoc, Pht, Tos, Tfa, Trt, Dmb, PMB or Bn;

[0020] X=Cl, Br or I.

[0021] Furthermore, in the step (d), an acid binding agent is added, and the acid binding agent is selected from an organic base and / or an inorganic base, the organic base is selected from one or a combination of diethylamine, triethylamine, tert-butylamine, pyridine or N,N-diisopropylethylamine, and the inorganic base is selected from one or a combination of ammonia water, sodium carbonate, potassium carbonate, sodium hydroxide or potassium hydroxide.

[0022] Furthermore, in step (d), the acid binding agent is selected from one or a combination of diethylamine, triethylamine, sodium carbonate or potassium carbonate.

[0023] Furthermore, the preparation method of the compound of formula III comprises the following steps: (c) reacting the compound of formula II with 2-(2H-1,2,3-triazol-2-yl)-5-methylbenzoyl chloride to obtain the compound of formula III, and the reaction formula is as follows:

[0024]

[0025] Wherein, R shown in the structural formula of the compound of formula II and the compound of formula III is selected from Cbz, Boc, Fmoc, Teoc, Pht, Tos, Tfa, Trt, Dmb, PMB or Bn.

[0026] Furthermore, in the step (c), an acid binding agent is also added, and the acid binding agent is selected from an organic base and / or an inorganic base, the organic base is selected from one or a combination of diethylamine, triethylamine, tert-butylamine, pyridine or N,N-diisopropylethylamine, and the inorganic base is selected from one or a combination of ammonia water, sodium carbonate, potassium carbonate, sodium hydroxide or potassium hydroxide.

[0027] Furthermore, in step (c), the acid binding agent is selected from one or a combination of diethylamine, triethylamine, sodium carbonate or potassium carbonate.

[0028] Furthermore, the preparation method of the compound of formula II comprises the following steps: (b) reacting the compound of formula I, Ph3PCH3Br and an alkaline reagent to obtain the compound of formula II, and the reaction formula is as follows:

[0029]

[0030] Wherein, R shown in the structural formula of the compound of formula I and the compound of formula II is selected from Cbz, Boc, Fmoc, Teoc, Pht, Tos, Tfa, Trt, Dmb, PMB or Bn;

[0031] The alkaline reagent is selected from one or a combination of sodium tert-butoxide, potassium tert-butoxide, sodium amide, sodium methoxide, sodium ethoxide, potassium carbonate or sodium carbonate.

[0032] The α-H acidity of Ph3PCH3Br in the present invention is relatively weak, and an alkaline reagent is required to generate ylide Ph3P=Ch2. The newly generated ylide is highly active and is a strong nucleophilic reagent similar to the Grignard reagent. It can react rapidly with the compound of formula I under mild conditions to obtain the olefin of the compound of formula II.

[0033] Furthermore, the preparation method of the compound of formula I comprises the following steps: (a) reacting NR-1,2-ethylenediamine with acetyl chloride to obtain the compound of formula I, and the reaction formula is as follows:

[0034]

[0035] Wherein, NR-1,2-ethylenediamine and R shown in the structural formula of the compound of formula I are selected from Cbz, Boc, Fmoc, Teoc, Pht, Tos, Tfa, Trt, Dmb, PMB or Bn.

[0036] The present invention uses R-protected 1,2-ethylenediamine as a starting raw material, does not need to use chiral raw materials, and the raw materials are easy to obtain, thereby greatly reducing the cost of raw materials.

[0037] Furthermore, in the step (a), an acid binding agent is added, and the acid binding agent is selected from an organic base and / or an inorganic base, the organic base is selected from one or a combination of diethylamine, triethylamine, tert-butylamine, pyridine or N,N-diisopropylethylamine, and the inorganic base is selected from one or a combination of ammonia water, sodium carbonate, potassium carbonate, sodium hydroxide or potassium hydroxide.

[0038] Furthermore, in step (a), the acid binding agent is selected from one or a combination of diethylamine, triethylamine, sodium carbonate or potassium carbonate.

[0039] Further, wherein R is selected from Cbz, Boc, Tos or Bn.

[0040] Furthermore, the preparation method of the compound of formula V comprises the following steps:

[0041] (a) adding NR-1,2-ethylenediamine, acetyl chloride and an acid binding agent to a solvent to react to obtain a compound of formula I, wherein the reaction formula is as follows:

[0042]

[0043] (b) adding the compound of formula I, Ph3PCH3Br and an alkali reagent to a solvent to react to obtain a compound of formula II, the reaction formula is as follows:

[0044]

[0045] (c) adding the compound of formula II, 2-(2H-1,2,3-triazole-2-yl)-5-methylbenzoyl chloride and an acid binding agent to a solvent for reaction to obtain a compound of formula III, wherein the reaction formula is as follows:

[0046]

[0047] (d) adding the compound of formula III, 4-halobutene and an acid binding agent to a solvent to react to obtain a compound of formula IV, wherein the reaction formula is as follows:

[0048]

[0049] (e) adding the compound of formula IV and Grubbs catalyst into a solvent to react to obtain a compound of formula II, the reaction formula is as follows:

[0050]

[0051] Wherein, R shown in the structural formula of NR-1,2-ethylenediamine, the compound of formula I, the compound of formula II, the compound of formula III, the compound of formula IV and the compound of formula V is selected from Cbz, Boc, Tos or Bn; X=Br.

[0052] The preparation route of the suvorexan intermediate obtained by optimizing the conditions of the present invention has mild reaction conditions and is easy to control. The yield and purity of the suvorexan intermediate are both considerable and easy to industrialize.

[0053] Furthermore, in step (a), the solvent is selected from one or a combination of dichloromethane, acetonitrile, tetrahydrofuran or 1,4-dioxane.

[0054] Furthermore, in step (b), the solvent is selected from one or a combination of dichloromethane, acetonitrile, tetrahydrofuran or 1,4-dioxane.

[0055] Furthermore, in step (c), the solvent is selected from one or a combination of dichloromethane, acetonitrile, tetrahydrofuran or 1,4-dioxane.

[0056] Furthermore, in step (d), the solvent is selected from one or a combination of dichloromethane, acetonitrile, tetrahydrofuran or 1,4-dioxane.

[0057] Furthermore, in step (e), the solvent is selected from toluene, xylene or NMP (N-methylpyrrolidone) or a combination of them.

[0058] As a second aspect of the present invention, the present invention provides a suvorexant intermediate prepared by the above preparation method.

[0059] Furthermore, the intermediates of suvorexant include compounds of formula IV and formula V.

[0060] The intermediates of suvorexant of the present invention include but are not limited to compounds of formula IV and formula V. The products involved in each step of the preparation method can be used as intermediates of suvorexant.

[0061] As a third aspect of the present invention, the present invention provides a suovorexin intermediate prepared by the above preparation method or use of the above suovorexin intermediate in preparing suovorexin.

[0062] Furthermore, the preparation method of suvorexant comprises the following steps: (f) subjecting the compound of formula V to optional amino deprotection, catalytic hydrogenation and chiral resolution reaction to obtain the compound of formula VII, the reaction formula is as follows:

[0063]

[0064] (g) The compound of formula VII is reacted with 2,5-dichlorobenzoxazole to obtain suvorexant, and the reaction formula is as follows:

[0065]

[0066] Wherein, R shown in the structural formula of the compound of formula V is selected from Cbz, Boc, Fmoc, Teoc, Pht, Tos, Tfa, Trt, Dmb, PMB or Bn.

[0067] It should be noted that in the step (f), whether to perform the amino deprotection reaction depends on the protecting group selected from R. For example, when R is selected from Cbz, PMB or Bn, R can be removed by catalytic hydrogenation, so there is no need to perform the amino deprotection reaction; when R is selected from Boc, Fmoc, Teoc, Pht, Tos, Tfa, Trt or Dmb, R cannot be removed by catalytic hydrogenation, so there is a need to perform the amino deprotection reaction.

[0068] It should be noted that the catalyst used in the catalytic hydrogenation includes but is not limited to Pd / C or Raney nickel.

[0069] Compared with the prior art, the present invention has the following beneficial effects:

[0070] The preparation method of the suvorexan intermediate provided by the present invention innovatively uses the Grubbs catalyst (Grubbs second-generation catalyst) for the construction of the suvorexan intermediate seven-membered nitrogen-containing chiral heterocycle, uses R-group-protected 1,2-ethylenediamine as a starting raw material, does not need to use a chiral raw material, the raw material is easy to obtain, and the cost is low, does not need to use the flammable and highly toxic compound methyl vinyl ketone, does not need to use flammable and explosive toxic gases, does not need to react under strong acid, strong base and high temperature conditions, can avoid the generation of a large amount of acid solution, alkali solution and high-temperature operation, has mild reaction conditions, is green and environmentally friendly, has a high safety factor, and is easy to industrialize.

[0071] The intermediate prepared by the present invention is used to prepare suovolexin, which provides a new idea for effectively preparing suovolexin. The obtained product is of high quality and can meet the pharmaceutical level. DETAILED DESCRIPTION

[0072] The embodiments of the present invention will be described in detail below in conjunction with the examples, but those skilled in the art will appreciate that the following examples are only used to illustrate the present invention and should not be considered to limit the scope of the present invention. If no specific conditions are specified in the examples, conventional conditions are used. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0073] Example 1 Preparation of Compounds of Formula I

[0074] Example 1-1

[0075]

[0076] Example 1-1a

[0077] 16.0 g of N-tert-butoxycarbonyl-1,2-ethylenediamine and 14.0 mL of triethylamine were added to 200 mL of dichloromethane, and 11.8 g of acetyl chloride was slowly added dropwise. After the addition, the mixture was reacted at room temperature. TLC showed that there was no N-tert-butoxycarbonyl-1,2-ethylenediamine. Water was added to quench the reaction, and the organic phase was separated, washed with water, dried, and filtered to obtain the organic phase, which was concentrated to dryness to obtain 19.1 g of the compound of formula I in a yellow liquid state, with a yield of 94.6% and a purity of 97.8% by HPLC.

[0078] Example 1-1b

[0079] The difference between this embodiment and embodiment 1-1a is that triethylamine is not added, and the other conditions are the same. After post-treatment, 15.2 g of yellow liquid compound of formula I is obtained with a yield of 75.3% and a HPLC purity of 87.8%.

[0080] Example 1-2

[0081]

[0082] 19.4 g of N-benzyloxycarbonyl-1,2-ethylenediamine and 12.4 mL of diethylamine were added to 250 mL of acetonitrile, and 8.6 g of acetyl chloride was slowly added dropwise. After the addition was completed, the reaction was carried out at room temperature. TLC was performed until there was no N-benzyloxycarbonyl-1,2-ethylenediamine. Water was added to quench the reaction, and the organic phase was extracted with dichloromethane, separated, washed with water, dried, and filtered to obtain an organic phase, which was concentrated to dryness to obtain 21.8 g of a yellow liquid compound of formula I, with a yield of 92.4% and a HPLC purity of 96.5%.

[0083] Examples 1-3

[0084]

[0085] 21.4 g of N-toluenesulfonyl-1,2-ethylenediamine and 10.6 g of sodium carbonate were added to 280 mL of tetrahydrofuran, and 114.1 g of acetyl chloride was slowly added dropwise. After the addition, the mixture was reacted at room temperature. TLC was performed until there was no N-toluenesulfonyl-1,2-ethylenediamine. Water was added to quench the reaction, and the mixture was extracted with ethyl acetate. The organic phase was separated, washed with water, dried, and filtered to obtain the organic phase. The organic phase was concentrated to dryness to obtain 23.4 g of the compound of formula I in a yellow liquid state, with a yield of 91.4% and a purity of 96.3% by HPLC.

[0086] Examples 1-4

[0087]

[0088] 15.0 g of N-benzyl-1,2-ethylenediamine and 13.8 g of potassium carbonate were added to 300 mL of 1,4-dioxane, and 15.7 g of acetyl chloride was slowly added dropwise. After the addition, the mixture was reacted at room temperature. TLC showed that there was no N-benzyl-1,2-ethylenediamine. Water was added to quench the reaction, and the mixture was extracted with dichloromethane. The organic phase was separated, washed with water, dried, and filtered to obtain the organic phase. The organic phase was concentrated to dryness to obtain 17.7 g of the compound of formula I in a yellow liquid state, with a yield of 92.2% and a purity of 97.0% by HPLC.

[0089] Example 2 Preparation of Compound of Formula II

[0090] Example 2-1

[0091]

[0092] 71.4 g of Ph3PCH3Br was added to 500 mL of tetrahydrofuran, and 22.4 g of potassium tert-butoxide was added at 0°C, and the reaction was continued for 1 h. 20.2 g of the compound of formula I was dissolved in 100 mL of tetrahydrofuran and added dropwise to the above reaction solution at 0°C. After the addition, the temperature was raised to room temperature for reaction, and TLC was performed until there was no compound of formula I. Rochelle salt aqueous solution was added, and the mixture was extracted with dichloromethane, and the organic phase was separated, washed with water, and dried to obtain the organic phase, which was concentrated to dryness to obtain 17.0 g of the compound of formula II as a yellow oil, with a yield of 85.0% and a HPLC purity of 96.5%.

[0093] Example 2-2

[0094]

[0095] 64.3 g of Ph3PCH3Br was added to 480 mL of dichloromethane, and 17.3 g of sodium tert-butoxide was added at 0°C. The reaction was continued for 1 h. 23.6 g of the compound of formula I was dissolved in 96 mL of dichloromethane and added dropwise to the above reaction solution at 0°C. After the addition, the temperature was raised to room temperature for reaction. TLC was performed until there was no compound of formula I. Rochelle salt aqueous solution was added, and the mixture was extracted with ethyl acetate. The organic phase was separated, washed with water, and dried to obtain the organic phase, which was concentrated to dryness to obtain 19.7 g of the compound of formula II as a yellow oil, with a yield of 84.2% and a HPLC purity of 95.9%.

[0096] Example 2-3

[0097]

[0098] 53.6 g of Ph3PCH3Br was added to 400 mL of acetonitrile, and 10.2 g of sodium ethoxide was added at 0°C. The reaction was continued for 1 h. 25.6 g of the compound of formula I was dissolved in 80 mL of acetonitrile and added dropwise to the above reaction solution at 0°C. After the addition, the temperature was raised to room temperature for reaction. TLC was performed until there was no compound of formula I. Rochelle salt aqueous solution was added, and the mixture was extracted with ethyl acetate. The organic phase was separated, washed with water, and dried to obtain the organic phase. The organic phase was concentrated to dryness to obtain 21.6 g of the compound of formula II as a yellow oil, with a yield of 83.3% and a HPLC purity of 95.6%.

[0099] Embodiment 2-4

[0100]

[0101] 71.4 g of Ph3PCH3Br was added to 420 mL of 1,4-dioxane, and 16.6 g of potassium carbonate was added at 0°C. The reaction was continued for 1 h. 19.2 g of the compound of formula I was dissolved in 84 mL of 1,4-dioxane and added dropwise to the above reaction solution at 0°C. After the addition, the temperature was raised to room temperature for reaction. TLC showed that there was no compound of formula I. Rochelle salt aqueous solution was added, and the mixture was extracted with ethyl acetate. The organic phase was separated, washed with water, and dried to obtain the organic phase. The organic phase was concentrated to dryness to obtain 15.6 g of the compound of formula II as a yellow oil, with a yield of 82.1% and a HPLC purity of 93.2%.

[0102] Example 3 Preparation of Compound of Formula III

[0103] Example 3-1

[0104]

[0105] Example 3-1a

[0106] 20.0 g of compound II and 14.0 mL of triethylamine were added to 200 mL of dichloromethane, 33.2 g of 2-(2H-1,2,3-triazole-2-yl)-5-methylbenzoyl chloride was dissolved in 100 mL of dichloromethane, and the dichloromethane solution of 2-(2H-1,2,3-triazole-2-yl)-5-methylbenzoyl chloride was slowly added dropwise, and the reaction was carried out at room temperature after the addition. TLC was performed until there was no compound II. Water was added to quench the reaction, and the organic phase was separated, washed with water, dried, filtered, and the organic phase was concentrated to dryness to obtain 36.6 g of off-white solid compound III, with a yield of 95.0% and a HPLC purity of 98.6%.

[0107] Example 3-1b

[0108] The difference between this embodiment and embodiment 3-1a is that triethylamine is not added, and the other conditions are the same. After post-treatment, 27.1 g of off-white solid compound of formula III is obtained, with a yield of 70.3% and a HPLC purity of 78.6%.

[0109] Example 3-2

[0110]

[0111] 23.4 g of compound II and 10.3 mL of diethylamine were added to 250 mL of acetonitrile, 24.4 g of 2-(2H-1,2,3-triazol-2-yl)-5-methylbenzoyl chloride was dissolved in 125 mL of acetonitrile, and the acetonitrile solution of 2-(2H-1,2,3-triazol-2-yl)-5-methylbenzoyl chloride was slowly added dropwise, and the reaction was carried out at room temperature after the addition. TLC was performed until there was no compound II. Water was added to quench the reaction, and the mixture was extracted with ethyl acetate, and the organic phase was separated, washed with water, dried, filtered, and the organic phase was concentrated to dryness to obtain 39.5 g of off-white solid compound III, with a yield of 94.3% and a HPLC purity of 97.8%.

[0112] Example 3-3

[0113]

[0114] 25.4 g of compound II and 10.6 g of sodium carbonate were added to 280 mL of tetrahydrofuran, 39.3 g of 2-(2H-1,2,3-triazol-2-yl)-5-methylbenzoyl chloride was dissolved in 140 mL of tetrahydrofuran, and the tetrahydrofuran solution of 2-(2H-1,2,3-triazol-2-yl)-5-methylbenzoyl chloride was slowly added dropwise, and the reaction was carried out at room temperature after the addition. TLC was performed until there was no compound II. Water was added to quench the reaction, and the mixture was extracted with dichloromethane, and the organic phase was separated, washed with water, dried, filtered, and the organic phase was concentrated to dryness to obtain 40.6 g of off-white solid compound III, with a yield of 92.5% and a HPLC purity of 96.3%.

[0115] Embodiment 3-4

[0116]

[0117] 19.0 g of compound II and 13.8 g of potassium carbonate were added to 300 mL of 1,4-dioxane, 44.3 g of 2-(2H-1,2,3-triazol-2-yl)-5-methylbenzoyl chloride was dissolved in 150 mL of 1,4-dioxane, and the 1,4-dioxane solution of 2-(2H-1,2,3-triazol-2-yl)-5-methylbenzoyl chloride was slowly added dropwise, and the mixture was reacted at room temperature after the addition was completed. TLC was performed until no compound II was present. Water was added to quench the reaction, and the mixture was extracted with ethyl acetate, and the organic phase was separated, washed with water, dried, and filtered to obtain the organic phase, which was concentrated to dryness to obtain 34.5 g of off-white solid compound III, with a yield of 92.0% and a HPLC purity of 95.7%.

[0118] Example 4 Preparation of Compound of Formula IV

[0119] Example 4-1

[0120]

[0121] Example 4-1a

[0122] 38.6 g of compound III and 13.8 g of potassium carbonate were added to 200 mL of dichloromethane, and 20.3 g of 4-bromobutene was slowly added dropwise at room temperature, and the mixture was heated to reflux for reaction, and TLC showed that no compound III was present. The mixture was cooled to room temperature, and water was added to quench the reaction, and the organic phase was separated, washed with water, dried, and filtered to obtain the organic phase, which was concentrated to dryness to obtain 38.2 g of off-white solid compound IV, with a yield of 87.0% and a purity of 96.6%.

[0123] Example 4-1b

[0124] The difference between this embodiment and embodiment 4-1a is that potassium carbonate is not added, and the other conditions are the same. After post-treatment, 29.5 g of off-white solid compound of formula IV is obtained, with a yield of 67.2% and a purity of 85.3%.

[0125] Example 4-2

[0126]

[0127] 41.9 g of compound III and 10.6 g of sodium carbonate were added to 250 mL of acetonitrile, 14.8 g of 4-bromobutene was slowly added dropwise at room temperature, and the mixture was heated to reflux for reaction. TLC showed that no compound III was present. The mixture was cooled to room temperature, and water was added to quench the reaction. The mixture was extracted with ethyl acetate, and the organic phase was separated, washed with water, dried, and filtered to obtain the organic phase. The organic phase was concentrated to dryness to obtain 40.4 g of off-white solid compound IV, with a yield of 85.4% and a purity of 96.3%.

[0128] Example 4-3

[0129]

[0130] 43.9 g of compound III and 14.0 mL of triethylamine were added to 280 mL of tetrahydrofuran, and 16.3 g of 4-chlorobutene was slowly added dropwise at room temperature. After the addition, the mixture was heated to reflux for reaction, and TLC was performed until no compound III was found. The mixture was cooled to room temperature, and water was added to quench the reaction. The mixture was extracted with dichloromethane, and the organic phase was separated, washed with water, dried, and filtered to obtain the organic phase. The organic phase was concentrated to dryness to obtain 41.6 g of off-white solid compound IV, with a yield of 84.2% and a purity of 95.6%.

[0131] Example 4-4

[0132]

[0133] 37.5 g of compound III and 10.3 mL of diethylamine were added to 300 mL of 1,4-dioxane, and 36.4 g of 4-iodobutene was slowly added dropwise at room temperature. After the addition, the mixture was heated to reflux for reaction. TLC showed that no compound III was present. The mixture was cooled to room temperature, and water was added to quench the reaction. The mixture was extracted with dichloromethane, and the organic phase was separated, washed with water, dried, and filtered to obtain the organic phase. The organic phase was concentrated to dryness to obtain 37.4 g of off-white solid compound IV, with a yield of 87.2% and a purity of 96.5%.

[0134] Example 5 Preparation of Compound of Formula V

[0135] Example 5-1

[0136]

[0137] Example 5-1a

[0138] 44.0 g of the compound of formula IV and 34.0 g of the second generation Grubbs catalyst were added to 500 mL of toluene and heated to 80°C for reaction. TLC was performed until no compound of formula IV was found. The mixture was cooled to room temperature and the insoluble matter was removed by filtration to obtain an organic phase, which was concentrated to dryness to obtain 29.9 g of an off-white solid compound of formula V, with a yield of 75.0% and a purity of 96.3%.

[0139] Example 5-1b

[0140] 44.0 g of the compound of formula IV and 42.5 g of the second generation Grubbs catalyst were added to 550 mL of xylene, heated to 80°C for reaction, and TLC was performed until no compound of formula IV was found. The mixture was cooled to room temperature, and the insoluble matter was removed by filtration to obtain an organic phase, which was concentrated to dryness to obtain 29.2 g of an off-white solid compound of formula V, with a yield of 73.3% and a purity of 95.2%.

[0141] Example 5-1c

[0142] 44.0 g of compound IV and 28.0 g of Grubbs second-generation catalyst were added to 450 mL of NMP, heated to 90°C for reaction, and TLC was performed until no compound IV was found. The mixture was cooled to room temperature, and the insoluble matter was removed by filtration to obtain an organic phase, which was concentrated to dryness to obtain 28.8 g of off-white solid compound V, with a yield of 72.4% and a purity of 95.5%.

[0143] Example 5-1d

[0144] The difference between this embodiment and embodiment 5-1a is that 44.0 g of compound IV and 42.5 g of Grubbs second-generation catalyst are used, and other conditions are the same. After post-treatment, 29.7 g of off-white solid compound V is obtained, with a yield of 74.6% and a purity of 96.1%.

[0145] Example 5-1e

[0146] The difference between this embodiment and embodiment 5-1a is that 44.0 g of compound IV and 28.0 g of Grubbs second-generation catalyst are used, and other conditions are the same. After post-treatment, 29.6 g of off-white solid compound V is obtained, with a yield of 74.4% and a purity of 96.0%.

[0147] Example 5-1f

[0148] The difference between this embodiment and embodiment 5-1a is that 44.0 g of compound IV and 8.5 g of Grubbs second-generation catalyst are used, and other conditions are the same. After post-treatment, 25.9 g of off-white solid compound V is obtained, with a yield of 65.1% and a purity of 93.3%.

[0149] Example 5-1g

[0150] The difference between this embodiment and embodiment 5-1a is that 44.0 g of compound IV and 85.0 g of Grubbs second-generation catalyst are used, and other conditions are the same. After post-treatment, 26.4 g of off-white solid compound V is obtained, with a yield of 66.3% and a purity of 92.3%.

[0151] Example 5-1h

[0152] The difference between this embodiment and embodiment 5-1a is that the reaction temperature is 70°C, and the other conditions are the same. After post-treatment, 29.5 g of off-white solid compound of formula V is obtained with a yield of 74.1% and a purity of 95.8%.

[0153] Example 5-1i

[0154] The difference between this embodiment and embodiment 5-1a is that the reaction temperature is 90°C, and the other conditions are the same. After post-treatment, 29.6 g of off-white solid compound of formula V is obtained with a yield of 74.5% and a purity of 96.0%.

[0155] Example 5-1j

[0156] The difference between this embodiment and embodiment 5-1a is that the reaction temperature is 100° C., and the other conditions are the same. After post-treatment, 24.7 g of off-white solid compound of formula V is obtained with a yield of 62.0% and a purity of 91.2%.

[0157] Example 5-1k

[0158] The difference between this embodiment and embodiment 5-1a is that the reaction temperature is 50°C, and the other conditions are the same. After post-treatment, 24.0 g of off-white solid compound of formula V is obtained with a yield of 60.3% and a purity of 91.6%.

[0159] Example 5-2

[0160]

[0161] 47.4 g of the compound of formula IV and 42.4 g of the second generation Grubbs catalyst were added to 550 mL of toluene, heated to 70°C for reaction, and TLC was performed until no compound of formula IV was found. The mixture was cooled to room temperature, and the insoluble matter was removed by filtration to obtain an organic phase, which was concentrated to dryness to obtain 31.5 g of an off-white solid compound of formula V, with a yield of 72.9% and a purity of 95.9%.

[0162] Example 5-3

[0163]

[0164] 49.3 g of compound IV and 29.7 g of Grubbs second-generation catalyst were added to 450 mL of NMP, heated to 75°C for reaction, and TLC was performed until no compound IV was found. The mixture was cooled to room temperature, and the insoluble matter was removed by filtration to obtain an organic phase, which was concentrated to dryness to obtain 32.4 g of off-white solid compound V, with a yield of 71.6% and a purity of 93.6%.

[0165] Example 5-4

[0166]

[0167] 43.0 g of the compound of formula IV and 28.0 g of the second generation Grubbs catalyst were added to 500 mL of xylene, heated to 90°C for reaction, and TLC was performed until no compound of formula IV was found. The mixture was cooled to room temperature, and the insoluble matter was removed by filtration to obtain an organic phase, which was concentrated to dryness to obtain 27.2 g of an off-white solid compound of formula V, with a yield of 70.2% and a purity of 91.2%.

[0168] Example 6 Preparation of Compound of Formula VII

[0169] Example 6-1

[0170]

[0171] 39.7 g of the compound of formula V was added to 200 mL of hydrogen chloride / ethyl acetate solution and reacted at room temperature. TLC showed no compound of formula V. The solution was concentrated to dryness to obtain 27.6 g of a white solid compound of formula VI, with a yield of 93.0% and a HPLC purity of 97.8%.

[0172] 14.8 g of the compound of formula VI was added to 250 mL of anhydrous methanol, and 1.5 g of Pd / C catalyst was added at room temperature to perform catalytic hydrogenation reaction until no compound of formula VI was found by TLC. The insoluble matter was removed by filtration to obtain an organic phase, which was concentrated to dryness and subjected to chiral separation to obtain 6.8 g of a white solid compound of formula VII, with a yield of 45.1% and a HPLC purity of 96.3%.

[0173] Example 6-2

[0174]

[0175] 43.2 g of the compound of formula V was added to 550 mL of anhydrous methanol, and 4.3 g of Pd / C catalyst was added at room temperature to carry out catalytic hydrogenation reaction, and TLC was performed until there was no compound of formula V. The insoluble matter was removed by filtration to obtain an organic phase, which was concentrated to dryness and then subjected to chiral separation to obtain 18.0 g of a white solid compound of formula VII, with a yield of 38.6% and a HPLC purity of 95.3%.

[0176] Example 6-3

[0177]

[0178] 45.4 g of the compound of formula V was added to 200 mL of hydrobromic acid / acetic acid solution, reacted at room temperature, and TLC was performed until no compound of formula V was found. The mixture was concentrated to dryness to obtain 27.6 g of the compound of formula VI as a white solid, with a yield of 92.3% and a purity of 96.8% by HPLC.

[0179] 14.8 g of the compound of formula VI was added to 260 mL of anhydrous ethanol, and 1.5 g of Pd / C catalyst was added at room temperature to carry out catalytic hydrogenation reaction, and TLC was performed until there was no compound of formula VI. The insoluble matter was removed by filtration to obtain an organic phase, which was concentrated to dryness and then subjected to chiral separation to obtain 12.9 g of a white solid compound of formula VII, with a yield of 43.2% and a HPLC purity of 95.7%.

[0180] Example 6-4

[0181]

[0182] 38.8 g of the compound of formula V was added to 500 mL of anhydrous ethanol, and 3.9 g of Pd / C catalyst was added at room temperature to carry out catalytic hydrogenation reaction, and TLC was performed until there was no compound of formula V. The insoluble matter was removed by filtration to obtain an organic phase, which was concentrated to dryness and then subjected to chiral separation to obtain 11.3 g of a white solid compound of formula VII, with a yield of 37.8% and a HPLC purity of 95.9%.

[0183] Example 7 Preparation of Suvorexant

[0184]

[0185] 30.0 g of the compound of formula VII and 13.8 g of potassium carbonate were added to 500 mL of dichloromethane, and 20.7 g of 2,5-dichlorobenzoxazole was slowly added dropwise at room temperature. After the addition, the mixture was heated to reflux for reaction, and TLC was performed until no compound of formula VII was found. The mixture was cooled to room temperature, and water was added to quench the reaction. The organic phase was separated, washed with water, dried, and filtered to obtain the organic phase, which was concentrated to dryness to obtain 39.7 g of off-white solid suvorexan, with a yield of 88.0% and a purity of 99.8% by HPLC.

[0186] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A method for preparing a suvorexant intermediate, characterized in that: The method comprises the following steps: (e) reacting a compound of formula IV under the action of a Grubbs second-generation catalyst to obtain a compound of formula V, and the reaction formula is as follows: Wherein, R shown in the structural formula of the compound of formula IV and the compound of formula V is selected from Cbz, Boc, Fmoc, Teoc, Pht, Tos, Tfa, Trt, Dmb, PMB or Bn.

2. The method for preparing a suvorexant intermediate according to claim 1, characterized in that: In the step (e), the reaction temperature is 70-90°C.

3. The method for preparing a suvorexant intermediate according to claim 1, characterized in that: In the step (e), the molar ratio of the compound of formula IV to the Grubbs second generation catalyst is (2-3):1.